OPCH Stock Alert: Halper Sadeh LLC is Investigating Whether Option Care Health, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC said it is investigating Option Care Health’s sale to CD&R and McKesson Corporation for $32.05 per share. The notice does not provide details on the investigation’s findings or the transaction terms beyond the per-share price.

Analysis

The investigation is a deal-process headline, not evidence that the board breached its duties or that the transaction is impaired. Its near-term importance is whether it creates a credible path to an injunction, shareholder vote delay, revised terms, or a competing bid; absent that, a plaintiff-firm announcement alone is weak evidence of a changed closing probability. For OPCH, the relevant market signal is the spread to the $32.05 consideration—not the headline itself. A wider spread could reflect deal risk, but may also be ordinary timing and liquidity compensation. For MCK, the main exposure is execution and strategic rationale; the available information does not establish the transaction’s financing, expected returns, or materiality to consolidated results, so avoid inferring a meaningful earnings impact. Over 1–3 months, monitor court filings, transaction documents, shareholder-vote timing, and any regulatory or financing conditions. Over 6–18 months, the thesis depends on closing and integration rather than this investigation. The key contrarian point: treating a law-firm investigation as proof of value left on the table risks overpricing litigation noise; dismissing a substantive challenge could understate timing and break risk.

Key Decisions for Investors

• OPCH: Do not trade solely on the investigation. For a merger-arbitrage position, first verify the current share price, full consideration and conditions, expected closing date, and any financing or regulatory contingencies; compare the implied spread with the downside if the deal breaks.
• Catalyst watch: Reassess only if a court filing seeks to block or materially delay closing, transaction disclosures reveal a credible process issue, the shareholder vote shifts, or a competing proposal emerges. These would change the probability-weighted value, not merely the headline risk.
• MCK: No standalone directional trade is supported by this item. Verify deal funding, expected returns, and management’s stated strategic rationale before underwriting any earnings or balance-sheet effect.
• Falsification: A prompt dismissal or resolution of the investigation alongside an unchanged transaction timetable would weaken the litigation-risk case; a court order, meaningful delay, changed terms, or termination would invalidate a low-risk closing assumption.